---
title: "XLDZ won the bid for a State Grid project worth 55.7756 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/258822124.md"
description: "XLDZ recently won the bid for a State Grid project, with a contract amount of 55.7756 million yuan, accounting for 7.28% of the 2024 operating income. The winning of this project will have a positive impact on the company's operating performance"
datetime: "2025-09-25T07:48:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/258822124.md)
  - [en](https://longbridge.com/en/news/258822124.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/258822124.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/258822124.md) | [繁體中文](https://longbridge.com/zh-HK/news/258822124.md)


# XLDZ won the bid for a State Grid project worth 55.7756 million yuan

According to the Zhitong Finance APP, XLDZ (002546.SZ) announced that the company recently received a bid notification from State Grid Corporation of China and State Grid Materials Co., Ltd., informing the company that it has been awarded the bid for "State Grid Corporation of China's 2025 53rd Batch Procurement (Second Measurement Equipment Tender for Marketing Project) (Tender No.: 0711-25OTL08322016)", winning a total of 5 packages with a total bid amount of 55.7756 million yuan, accounting for 7.28% of the company's operating income in 2024. The performance of the contract after winning the bid will have a positive impact on the company's operating results

### Related Stocks

- [xldz (002546.CN)](https://longbridge.com/en/quote/002546.CN.md)

## Related News & Research

- [08:15 ETDictionary.com's 2026 Winter Word Drop Embraces Innovation, Goes Global and Enters the Chat](https://longbridge.com/en/news/277470747.md)
- [08:03 ETDecentralized Clinical Trial Validates Novel "Fasting Mimetic" Formulation for Cardiometabolic Health](https://longbridge.com/en/news/277468910.md)
- [LibreOffice Online dragged out of the attic, dusted off for another go](https://longbridge.com/en/news/277439337.md)
- [Vial Doses First Patient for Phase 1 Trial of Vial’s IL-13 x TSLP, a Novel Bispecific Antibody](https://longbridge.com/en/news/277585325.md)
- [Think In Italian Unveils Free Preview of SpeakTwice Italian App](https://longbridge.com/en/news/277506153.md)